PreprintCited by 135Telomeres, Telomerase, and SenescenceCancer-related Molecular PathwaysGenetics, Aging, and Longevity in Model Organisms

Telomerase abrogation dramatically accelerates TRF2-induced epithelial carcinogenesis

Open access
Blanco, Raquel, Muñoz, Purificación, Flores, Juana M., Klatt, Peter, Blasco, María A.·2007·Genes & Development

Abstract

TRF2 is a telomere-binding protein with roles in telomere protection and telomere-length regulation. The fact that TRF2 is up-regulated in some human tumors suggests a role of TRF2 in cancer. Mice that overexpress TRF2 in the skin, K5TRF2 mice, show critically short telomeres and are susceptible to UV-induced carcinogenesis as a result of deregulated XPF/ERCC1 activity, a nuclease involved in UV damage repair. Here we demonstrate that, when in combination with telomerase deficiency, TRF2 acts as a very potent oncogene in vivo. In particular, we show that telomerase deficiency dramatically accelerates TRF2-induced epithelial carcinogenesis in K5TRF2/Terc−/− mice, coinciding with increased chromosomal instability and DNA damage. Telomere recombination is also increased in these mice, suggesting that TRF2 favors the activation of alternative telomere maintenance mechanisms. Together, these results demonstrate that TRF2 increased expression is a potent oncogenic event that along with telomerase deficiency accelerates carcinogenesis, coincidental with a derepression of telomere recombination. These results are of particular relevance given that TRF2 is up-regulated in some human cancers. Furthermore, these data suggest that telomerase inhibition might not be effective to cease the growth of TRF2-overexpressing tumors.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1101/gad.406207

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Mice with short telomeres are resistant to tumours, with a few exceptions, arguing that telomere shortening is a potent in vivo tumour suppressor mechanism.

    “Conversely, mice with short telomeres are resistant-with a few exceptions-to tumours 73 , arguing that telomere shortening represents a potent in vivo tumour suppressor mechanism.”

    From The common biology of cancer and ageing (2007) · cites this paper as [73]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 53 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. Zijlmans, J.M., Martens, U.M., Poon, S.S., Raap, A.K., Tanke, H.J., Ward, R.K., and Lansdorp, P.M. 1997. Telomeres in the mouse have large inter-chromosomal variations in the num- ber of T2AG3 repeats. Proc. Natl. Acad. Sci. 94: 7423-7428.

Cited by

Sorted by citations

Authors
Blanco, R., Muñoz, P., Flores, J. M., Klatt, P., & Blasco, M. A.
Affiliations
  • Spanish National Cancer Research Centre (ES)
  • Universidad Complutense de Madrid (ES)
Venue
Genes & Development
Published
2007-01-15
Volume
21
Issue
2
Pages
206-220
ISSN
  • 0890-9369 (ISSN-L)
  • 1549-5477
OpenAlex
W2049151391
Cited by
135
References
53
Citations by year
2025: 3 · 2024: 2 · 2023: 5 · 2022: 4 · 2021: 2 · 2020: 4 · 2019: 3 · 2018: 2 · 2017: 7 · 2016: 10 · 2015: 5 · 2014: 9 · 2013: 8 · 2012: 10
Type
posted content
Language
en
Open access
Locations
  • Genes & Development (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Physiology › Telomeres, Telomerase, and Senescence
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
Keywords
TRF2, telomerase deficiency, telomere-binding proteins, epithelial carcinogenesis, oncogenes, chromosomal instability, telomere recombination, UV-induced carcinogenesis, telomere length, DNA damage, telomerase inhibition
MeSH terms
Animals, Animals, Newborn, Disease Models, Animal, DNA Damage, Recombination, Genetic, Skin, Skin Neoplasms, Specific Pathogen-Free Organisms, Ultraviolet Rays, 9,10-Dimethyl-1,2-benzanthracene, Keratinocytes, Telomere, Telomerase, Telomeric Repeat Binding Protein 2, Chromosomal Instability, Mice, Keratin-5, Keratin-15

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review